THE CORRELATION BETWEEN TROPONIN I LEVEL WITH CORRECTED THROMBOLYSIS IN MYOCARDIAL INFARCTION FRAME COUNT IN PATIENTS WHOSE UNDERWENT PRIMARY PERCUTANEOUS CORONARY INTERVENTION: A SINGLE CENTER STUDY
Keywords:Corrected thrombolysis in myocardial infarction frame count, Troponin I, ST-elevation myocardial infarction, Primary percutaneous coronary intervention
Objective: There were studies reported about the correlation between troponin I with scale of myocardial infarction (MI) area. However, the effect of revascularization into the coronary flow has not been reported. We aim to determine the correlation between high sensitivity troponin I and the successfulness of revascularization primary percutaneous coronary intervention (PPCI) in ST-elevation MI (STEMI) patients. The successfulness of revascularization was assessed by calculating Corrected thrombolysis in MI frame count (CTFC).
Methods: This is a retrospective analysis including all consecutive patients undergoing PPCI over 1-year period from December 2018 to 2019 at the Integrated Heart Service Installation Dr. M. Djamil Padang Hospital, West Sumatra. Exclusion criteria included patients with incomplete medical record data, incomplete coronary angiography data, prior MI, and prior PCI and coronary artery bypass graft. Patients were put into two groups with normal (CTFC <30) and high (CTFC ≥30) to define the baseline characteristics.
Results: A retrospective analysis was performed of patients undergoing primary PCI. Ninety-six patients underwent PPCI between December 2018 and 2019 were enrolled. For the baseline characteristic, patient was divided into two groups with normal CTFC (<30) and high (CTFC ≥30). There was negative weak correlation between troponin I level and CTFC with Spearman’s correlation value was 0.371 and correlation coefficient −0.092.
Conclusion: Troponin I level at first presentation before revascularization did not have a significant correlation with coronary flow result after revascularization in STEMI patients.
Gurbuz AS, Ozturk S, Efe SC, Yilmaz MF, Yanik RE, Yaman A, et al. Heparanase is a predictive marker for high thrombus burden in patients with ST-segment elevation myocardial infarction. Biomarkers 2019;24:600-6.
Häcker U, Nybakken K, Perrimon N. Heparan sulphate proteoglycans: The sweet side of development. Nat Rev Mol Cell Biol 2005;6:530-41.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 2018;39:119-77.
Trihono T. Riset Kesehatan Dasar 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia; 2013. p. 1-306.
Dharma S. Infark miokard akut disertai elevasi segmen ST: Patologi, patofisiologi dan gambaran klinis. In: Buku Ajar Kardiovaskular. Vol. 2. Jakarta, Indonesia: Sagung Seto; 2017. p. 153-9.
Baxter R, Hastings N, Law A, Glass EJ. Effect of remote ischemic conditioning on clinical outcomes in patients presenting with a ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2008;39:561-3.
Schmidt MR, Rasmussen ME, Bøtker HE. Remote ischemic conditioning for patients with STEMI. J Cardiovasc Pharmacol Ther 2017;22:302-9.
Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
Brener SJ, Dizon JM, Mehran R, Guerchicoff A, Lansky AJ, Farkouh M, et al. Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: Analysis from the HORIZONS-AMI trial. Am Heart J 2013;166:676-83.
Vakili H, Sadeghi R, Rezapoor P, Gachkar L. In-hospital outcomes after primary percutaneous coronary intervention according to left ventricular ejection fraction. ARYA Atheroscler 2014;10:211-7.
Bagai A, Huang Z, Lokhnygina Y, Harrington RA, Armstrong PW, Strony J, et al. Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circ Cardiovasc Interv 2015;8:e002314.
Kim JY, Jeong MH, Ahn YK, Moon JH, Chae SC, Hur SH, et al. Decreased glomerular filtration rate is an independent predictor of in-hospital mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Korean Circ J 2011;41:184-90.
Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in myocardial infarction (TIMI) trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54.
Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, et al. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
Wanamaker BL, Seth MM, Sukul D, Dixon SR, Bhatt DL, Madder RD, et al. Relationship between troponin on presentation and in-hospital mortality in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Heart Assoc 2019;8:e013551.
Hamada S, Nishiue T, Nakamura S, Sugiura T, Kamihata H, Miyoshi H, et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. J Am Coll Cardiol 2001;38:666-71.
Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis in myocardial infarction (TIMI) study group. Circulation 1999;99:1945-50.
Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized efficacy study of tirofiban for outcomes and restenosis. J Am Coll Cardiol 1998;32:28-34.
Herrmann HC, Moliterno DJ, Ohman EM, Stebbins AL, Bode C, Betriu A, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) trial. J Am Coll Cardiol 2000;36:1489-96.
Antonsen L, Jensen LO, Terkelsen CJ, Tilsted H, Junker A, Maeng M, et al. Outcomes after primary percutaneous coronary intervention in octogenarians and nonagenarians with ST-segment elevation myocardial infarction: From the Western Denmark heart registry. Catheter Cardiovasc Interv 2013;81:912-9.
Maeng M, Nielsen PH, Busk M, Mortensen LS, Kristensen SD, Nielsen TT, et al. Time to treatment and three-year mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction a DANish trial in acute myocardial infarction-2 (DANAMI-2) substudy. Am J Cardiol 2010;105:1528-34.
Lu HT, Nordin R, Ahmad WA, Lee CY, Zambahari R, Ismail O, et al. Sex differences in acute coronary syndrome in a multiethnic Asian population: Results of the Malaysian national cardiovascular disease database acute coronary syndrome (NCVD-ACS) registry. Glob Heart 2014;9:381-90.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.